ASCO: MEDI4736 combined with tremelimumab results in acceptable toxicity in NSCLC patients
Results from a phase 1b study of MEDI4736 and tremelimumab show manageable toxicity and clinical activity in advanced NSCLC patients with and without PD-L1 tumor expression
2015-05-28
(Press-News.org) TAMPA, Fla. - Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer. Scott J. Antonia, M.D., Ph.D., chair of the Thoracic Oncology Department at Moffitt Cancer Center will be presenting data from a phase 1b dose-escalation and expansion study of MEDI4736 combined with tremelimumab at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.
MEDI4736 is a monoclonal antibody that targets the programmed cell death-1 ligand (PD-L1) expressed on tumor cells, and tremelimumab is a monoclonal antibody that inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) found on T cells. Activation of both PD-L1 and CTLA-4 pathways blocks the immune system and inhibits the generation of an immune response. Tumor cells take advantage of this physiological process to avoid immune detection and cell death. Inhibiting these proteins with MEDI4736 and tremelimumab restimulates the immune system to detect and destroy tumor cells.
The Moffitt team and their collaborators report that MEDI4736 combined with tremelimumab resulted in manageable toxicity, with 64 percent of patients experiencing adverse events. Patients who were administered higher doses of tremelimumab with a constant dose of MEDI4736 experienced more frequent and severe toxicities. The most common overall drug-related adverse events were fatigue (26 percent), diarrhea (21 percent), and increased amylase (13 percent). Thirty-one percent of patients had one or more grade 3/4 drug-related adverse event, with the most frequent being diarrhea (8 percent) and colitis (7 percent).
Results demonstrate that the combination of MEDI4736 and tremelimumab has clinical activity in NSCLC patients, including in patients who lack tumor expression of PD-L1. Out of 31 evaluable patients, 8 patients achieved a partial response and 11 patients had stable disease, while 3 out of 10 patients with PD-L1 negative tumors had a partial response.
The maximum-tolerated dose has yet to be defined and recruitment to the study is ongoing. Trial results to date will be presented during a poster discussion session on Saturday, May 30, 3-4:15 p.m. in room S406 and during the poster session from 8-11:30 a.m. in S Hall A.
INFORMATION:
About Moffitt Cancer Center
Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the top-ranked cancer hospital in the Southeast and has been listed in U.S. News & World Report as one of the "Best Hospitals" for cancer care since 1999. With more than 4,500 employees, Moffitt has an economic impact in Florida of nearly $1.6 billion. For more information, visit MOFFITT.org, and follow the Moffitt momentum on Facebook, Twitter and YouTube.
ELSE PRESS RELEASES FROM THIS DATE:
2015-05-28
TAMPA, Fla. - Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention - the use of agents to prevent the development or progression of prostate cancer. A team of researchers led by Nagi B. Kumar, Ph.D., R.D., F.A.D.A. at Moffitt Cancer Center recently published results of a randomized trial that assessed the safety and effectiveness of the active components in green tea to prevent prostate cancer development in men ...
2015-05-28
TAMPA, Fla. - Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months. Preclinical studies suggest that JAK2 inhibitors may be an effective treatment option for CMML. Eric Padron, M.D., assistant member of the Malignant Hematology Program at Moffitt Cancer Center will report on the first phase 1 study of the JAK2 inhibitor ruxolitinib in CMML patients ...
2015-05-28
TAMPA, Fla. - The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.
Nivolumab targets a protein called the programmed death-1 (PD-1) receptor. The ...
2015-05-28
Many living things can respond to electric fields, either moving or using them to detect prey or enemies. Weak electric fields may be important growth and development, and in wound healing: it's known that one of the signals that guides cells into a wound to repair it is a disturbance in the normal electric field between tissues. This ability to move in response to an electric field is called galvanotaxis or electrotaxis.
UC Davis dermatology professor Min Zhao, Peter Devroetes at Johns Hopkins University and colleagues hope to unravel how these responses work, studying ...
2015-05-28
Unstable funding is threatening the viability of academic biomedical research in this country, according to a new paper published this week in the journal Science Translational Medicine. The paper was written jointly by the deans of 19 prominent medical schools around the country. Among this group is University of Maryland School of Medicine Dean E. Albert Reece.
"We must reinvigorate the federal-academic partnership for research across all sciences," the authors write. If the current trends in funding continue, both established investigators and early-career scientists ...
2015-05-28
CHICAGO (May 28, 2015): Traumatic injury is the leading cause of death among people under age 45, but if trauma physicians could deliver plasma to these injury victims within minutes of their arrival in the emergency room, more of them would stand a better chance of survival.
When they arrive at the hospital, trauma victims can often wait 30 minutes or longer to receive plasma because the traditional way of giving them plasma involves two time-consuming steps: testing for blood type and then thawing frozen plasma. "There's a golden hour after trauma where you need to ...
2015-05-28
Using a complex modeling program that helps analyze the physical dynamics of large, structurally complex protein molecules, a research team has made progress towards finding a weak spot in the architecture of a group of enzymes that are essential to antibiotic resistance in a number of bacteria.
In an article published in PLOS ONE, University of North Carolina at Charlotte senior biology major Jenna R. Brown and her faculty mentor, UNC Charlotte professor of bioinformatics and genomics Dennis R. Livesay, present an analysis of the four currently known protein structures ...
2015-05-28
Immune cells play an important role in the upkeep and repair of our bodies, helping us to defend against infection and disease. Until now, how these cells detect a wounded or damaged site has largely remained a mystery. New research, led by University of Bristol academics in collaboration with a team from the University of Sheffield, has identified the triggers which lead these cells to react and respond in cell repair.
It is hoped the findings, published in Current Biology, could help scientists design therapies to manipulate the cell repair process and direct immune ...
2015-05-28
Flies might be smarter than you think. According to research reported in the Cell Press journal Current Biology on May 28, fruit flies know what time of day it is. What's more, the insects can learn to connect different scents with the sweet reward of sugar, depending on the hour: menthol in the morning and mushrooms in the afternoon.
Researchers say that the findings show the surprising mental abilities of animals, no matter how small.
"If even the fly, with its miniature brain, has the sense of time, most animals may have it," says Martin Heisenberg of Rudolf Virchow ...
2015-05-28
Controlling bacterial infections responsible for typhoid fever could dramatically reduce the risk of gallbladder cancer in India and Pakistan, according to a study published by Cell Press May 28th in Cell Host & Microbe. The findings establish for the first time the causal link between bacterial infection and gallbladder cancer, explaining why this type of cancer is rare in the West but common in India and Pakistan, where typhoid fever is endemic. Public policy changes inspired by this research could have an immediate impact on preventing a type of cancer that currently ...
LAST 30 PRESS RELEASES:
[Press-News.org] ASCO: MEDI4736 combined with tremelimumab results in acceptable toxicity in NSCLC patients
Results from a phase 1b study of MEDI4736 and tremelimumab show manageable toxicity and clinical activity in advanced NSCLC patients with and without PD-L1 tumor expression
